Last reviewed · How we verify
Kanitinib
Kanitinib is a Small molecule drug developed by Beijing Konruns Pharmaceutical Co., Ltd.. It is currently in Phase 1 development. Also known as: CX1003.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Kanitinib |
|---|---|
| Also known as | CX1003 |
| Sponsor | Beijing Konruns Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase 1 Study of CX1003 (Kanitinib) in Patients with Advanced Solid Tumors (PHASE1)
- Kanitinib in Treating Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Kanitinib CI brief — competitive landscape report
- Kanitinib updates RSS · CI watch RSS
- Beijing Konruns Pharmaceutical Co., Ltd. portfolio CI
Frequently asked questions about Kanitinib
What is Kanitinib?
Who makes Kanitinib?
Is Kanitinib also known as anything else?
What development phase is Kanitinib in?
Related
- Manufacturer: Beijing Konruns Pharmaceutical Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: CX1003
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing